Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04501731
Other study ID # 20047
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 28, 2022
Est. completion date December 31, 2022

Study information

Verified date September 2021
Source University of Nottingham
Contact Caroline Blanchard
Email caroline.blanchard@nottingham.ac.uk
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Posterior fossa tumours (PFT) account for 2/3 of childhood brain cancers. They can be highly malignant requiring combined chemotherapy and radiotherapy post-surgery for a >50% chance of cure. PFT frequently involve the cerebellum which is responsible for coordinating movement, balance, emotional control, and links closely to control of affect and executive function. PFT survivors show highly variable profiles for cognitive and sensorimotor functioning which are influenced strongly by the severity of the pre-diagnostic or post-surgical brain injury State-of-the-art magnetic resonance imaging (MRI) scans can allow to measure a variety of different biological processes in the brain, and the investigators believe that some of these MRI measures (called MRI biomarkers) have the potential to improve our ability to understand and monitor consequences of the ablative brain surgery and complex mechanisms of motor skills recovery. Biomarkers are very important for the development of intervention because 1) they help understand the recuperation process and 2) they allow to effectively assess whether or not a treatment or intervention works. Transcranial magnetic stimulation (TMS) is a powerful non-invasive neuro-modulatory intervention that has the potential to evaluate the integrity of the nervous tracts from the brain to the hand. It is a procedure that applies magnetic pulses on the surface of the scalp to reach underlying brain tissue. TMS has built a reputable status among neuro-rehabilitative research, and there is currently a major effort to translate the positive research findings into clinically useful therapeutic strategies. This study is therefore an important first step towards understanding how potential MRI biomarkers and responses to TMS relate to motor symptoms in PFT young survivors. Once completed, this study will allow the investigators to select the most promising MRI biomarkers and TMS protocols to take forward into future treatment trials. The investigators aim to stimulate the recovery of coordination skills, help the development of targeted therapies, and consequently improve long-term quality of life in children and young people with history of brain tumour. The proposed research intends to prove the feasibility of such brain stimulation and imaging and collect some preliminary measures


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 31, 2022
Est. primary completion date July 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years to 22 Years
Eligibility Inclusion Criteria: - Able to undergo MRI scan without sedation or general anaesthetic - Able to give informed consent. Exclusion Criteria: - History of seizure - Current cancer or post surgery treatment - Contraindication to TMS or MRI - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Transcranial Magnetic Stimulation (TMS)
With the TMS session we gather information about nerve fibres from the brain to the hand. It will last around 2 hours and 30 minutes.
Magnetic Resonance Imaging (MRI)
With the MRI scan we will gather information about the brain structure and function. This will last around 30 minutes.
Motor assessment
The motor assessment includes a pegboard game, a "grab the alien nose" game and measure of your maximum grip force. In total it will last around 30 minutes.
Questionnaires
Feasibility, tolerability of such intervention as well as quality of life of PFT survivors will be assessed thanks to questionnaires.

Locations

Country Name City State
United Kingdom Queen's Medical Centre Nottingham

Sponsors (3)

Lead Sponsor Collaborator
University of Nottingham Nottingham Hospitals Charity, Nottingham University Hospital NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary 5C-pilot Satisfaction Questionnaire Participants rating their experience of MRI, TMS and motor assessment 6 months
Primary Completion rate of the sessions of TMS, MRI and motor tasks Measure of quality of MRI images (participants motion) - Feasibility will be confirmed if 50% or more of these participants complete the TMS session 6 months
Secondary Anatomical MRI metrics (PFT vs control) Cerebellar volumetry and cerebellar parcellation - after surgery (mm3) 1 year
Secondary fMRI metrics (PFT vs control) Functional connectivity within sensorimotor network (activation map) 1 year
Secondary Diffusion MRI metrics (PFT vs control) Anatomical connectivity within sensorimotor network (tractography) 1 year
Secondary Single-pulse TMS metrics (PFT vs control) Resting motor threshold (Stimulus intensity expressed as a percentage of maximal stimulator output) 1 year
Secondary Single-pulse TMS metrics (PFT vs control) input-output curve 1 year
Secondary Single-pulse TMS metrics (PFT vs control) Silent period (ms) 1 year
Secondary Single-pulse TMS metrics (PFT vs control) Short-afferent inhibition 1 year
Secondary Dual-pulse TMS metrics (PFT vs control) Intracortical & long-latency inhibition and facilitation 1 year
Secondary Dual-pulse TMS metrics (PFT vs control) cerebellar-motor inhibition 1 year
Secondary Motor performance (PFT vs control) - Reaching and grasping task Kinematic parameters of movement 1 year
Secondary Motor performance (PFT vs control) - Grooved pegboard Score 1 year
Secondary Motor performance (PFT vs control) - Grip force Maximum force (N) 1 year
Secondary Quality of life of PFT survivors: FACT-Peds-Br Questionnaire FACT-Peds-Br Pediatric Questionnaire - For patients with Brain cancer 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05023434 - A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Completed NCT04114786 - 3D Printed Mask for GBM and Brain Mets N/A
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT02852655 - A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma Phase 1
Completed NCT02911155 - Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Completed NCT00329589 - A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients Phase 1
Completed NCT01650922 - Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples N/A
Completed NCT00505141 - Urban Environmental Exposures and Childhood Cancer N/A
Completed NCT00504660 - 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients Phase 2
Completed NCT00979810 - Image-Guided Stereotactic Biopsy of High Grade Gliomas N/A
Recruiting NCT04899908 - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases Phase 2
Active, not recruiting NCT02851706 - Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Completed NCT01012609 - External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas Phase 2
Completed NCT00782756 - Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma Phase 2
Terminated NCT03149575 - VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Phase 3
Completed NCT01974804 - Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
Withdrawn NCT01320787 - 18-F-Fluoroacetate as PET Imaging Agent Phase 1